Review

Blood Pressure Monitoring in Cardiovascular Disease

  • While the practice of taking blood pressure readings at the physician’s office continues to be valid, home blood pressure monitoring is being increasingly used to enhance diagnostic accuracy and ensure a more personalized follow-up of patients. In the case of white coat hypertension and resistant arterial hypertension, ambulatory blood pressure monitoring is indispensable. Recent studies attach great importance to nocturnal blood pressure patterns, with a reduction in these becoming a treatment goal, a strategy known as chronotherapy. Home blood pressure monitoring is useful for both diagnosis and follow-up of arterial hypertension. Its use, particularly if combined with other patient-support interventions, serves to improve blood pressure control. Telemonitoring is associated with a decrease in blood pressure values and an increase in patient satisfaction. All studies highlight the importance of patients being supported by a multidisciplinary health care team, since blood pressure telemonitoring with a support team is more effective than simple data telemonitoring. Further studies are called for, especially on the illiterate population, with difficulties posed by technological accessibility and transcriptions into different languages. More cost-effectiveness studies and long-term results are needed to ascertain the true benefit of blood pressure telemonitoring.

    Citation: Carlos Menéndez Villalva, Xose Luis Muiño López-Alvarez, Martín Menéndez Rodríguez, María José Modroño Freire, Olalla Quintairos Veloso, Lea Conde Guede, Sandra Vilchez Dosantos, Manuel Blanco Ramos. Blood Pressure Monitoring in Cardiovascular Disease[J]. AIMS Medical Science, 2017, 4(2): 164-191. doi: 10.3934/medsci.2017.2.164

    Related Papers:

    [1] Mario Grassi, Giuseppe Pontrelli, Luciano Teresi, Gabriele Grassi, Lorenzo Comel, Alessio Ferluga, Luigi Galasso . Novel design of drug delivery in stented arteries: A numerical comparative study. Mathematical Biosciences and Engineering, 2009, 6(3): 493-508. doi: 10.3934/mbe.2009.6.493
    [2] Adam Peddle, William Lee, Tuoi Vo . Modelling chemistry and biology after implantation of a drug-eluting stent. Part Ⅱ: Cell proliferation. Mathematical Biosciences and Engineering, 2018, 15(5): 1117-1135. doi: 10.3934/mbe.2018050
    [3] Nilay Mondal, Koyel Chakravarty, D. C. Dalal . A mathematical model of drug dynamics in an electroporated tissue. Mathematical Biosciences and Engineering, 2021, 18(6): 8641-8660. doi: 10.3934/mbe.2021428
    [4] Xiaobing Feng, Tingao Jiang . Mathematical and numerical analysis for PDE systems modeling intravascular drug release from arterial stents and transport in arterial tissue. Mathematical Biosciences and Engineering, 2024, 21(4): 5634-5657. doi: 10.3934/mbe.2024248
    [5] Cameron Meaney, Gibin G Powathil, Ala Yaromina, Ludwig J Dubois, Philippe Lambin, Mohammad Kohandel . Role of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach. Mathematical Biosciences and Engineering, 2019, 16(6): 6257-6273. doi: 10.3934/mbe.2019312
    [6] Saied M. Abd El-Atty, Konstantinos A. Lizos, Osama Alfarraj, Faird Shawki . Internet of Bio Nano Things-based FRET nanocommunications for eHealth. Mathematical Biosciences and Engineering, 2023, 20(5): 9246-9267. doi: 10.3934/mbe.2023405
    [7] Hatim Machrafi . Nanomedicine by extended non-equilibrium thermodynamics: cell membrane diffusion and scaffold medication release. Mathematical Biosciences and Engineering, 2019, 16(4): 1949-1965. doi: 10.3934/mbe.2019095
    [8] Avner Friedman, Najat Ziyadi, Khalid Boushaba . A model of drug resistance with infection by health care workers. Mathematical Biosciences and Engineering, 2010, 7(4): 779-792. doi: 10.3934/mbe.2010.7.779
    [9] John Boscoh H. Njagarah, Farai Nyabadza . Modelling the role of drug barons on the prevalence of drug epidemics. Mathematical Biosciences and Engineering, 2013, 10(3): 843-860. doi: 10.3934/mbe.2013.10.843
    [10] R. A. Everett, Y. Zhao, K. B. Flores, Yang Kuang . Data and implication based comparison of two chronic myeloid leukemia models. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1501-1518. doi: 10.3934/mbe.2013.10.1501
  • While the practice of taking blood pressure readings at the physician’s office continues to be valid, home blood pressure monitoring is being increasingly used to enhance diagnostic accuracy and ensure a more personalized follow-up of patients. In the case of white coat hypertension and resistant arterial hypertension, ambulatory blood pressure monitoring is indispensable. Recent studies attach great importance to nocturnal blood pressure patterns, with a reduction in these becoming a treatment goal, a strategy known as chronotherapy. Home blood pressure monitoring is useful for both diagnosis and follow-up of arterial hypertension. Its use, particularly if combined with other patient-support interventions, serves to improve blood pressure control. Telemonitoring is associated with a decrease in blood pressure values and an increase in patient satisfaction. All studies highlight the importance of patients being supported by a multidisciplinary health care team, since blood pressure telemonitoring with a support team is more effective than simple data telemonitoring. Further studies are called for, especially on the illiterate population, with difficulties posed by technological accessibility and transcriptions into different languages. More cost-effectiveness studies and long-term results are needed to ascertain the true benefit of blood pressure telemonitoring.


    The tumor microenvironment (TME) is a complex ecosystem comprising numerous cells, including immune cells, stromal cells and immunosuppressive cells [1]. Tumour endothelial cells (TECs) are a prominent component of TME and TECs, which have critical functions on tumor growth, progression and metastasis [2]. As tumor angiogenesis is essential for tumor growth and metastasis, inducing tumor-associated angiogenesis is a promising tactic in cancer progression [3]. Angiogenesis is now accepted as an important hallmark of cancer [4] and endothelial cells (which form tight adhesions to ensure vessel integrity) are essentials in inducing angiogenesis in TME [3]. In TME, TECs interact with tumor cells via juxtacrine and paracrine signaling during tumor intravasation and metastasis [5].

    Colorectal cancer (CRC) is the fourth most common cancer and a leading cause of cancer mortality worldwide [6]. Recently stated that distinct stromal transcriptional and interactions are altered in colon cancer development [7] and stromal cells contribute to the CRC transcriptome [8]. It was also stated that stromal gene expression defines poor prognosis in colorectal cancer [9] and induces poor-prognosis subtypes in colorectal cancer [10]. Altogether, stromal cells have substantial influence and regulatory roles in colon cancer and endothelial cells (ECs) may cause colon carcinogenesis as a part of the stromal component.

    So, analyzing the transcriptomes of colon TECs (CTECs) in TME reveals new targets and avenues and explores more uncontrolled factors in colon cancer research. We present a comprehensive analysis through bioinformatic tools and identified molecular and genetic alterations in TECs. We identified DEGs from microarray datasets of gene expression omnibus (GEO), hub genes from the interactions of deregulated genes and find out significant KEGG pathways. We also identified significant hub genes that are linked with poor survival of patients. Moreover, we found that hub genes are associated with immune cells infiltration and positively correlated with immune suppressive markers. This integrated analysis provides vital molecular insights into CTECs characterization, which may directly affect treatment recommendations for colon cancer patients. It provides opportunities for genome-guided clinical trials as well as drug development for the treating of colon cancer patients.

    We searched the NCBI gene expression omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) using the keywords "colon cancer endothelial cells, " "endothelial cells, " and "normal endothelial cells, " and identified one CTECs gene expression dataset GSE89287 (n = 24) (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89287) [11]. This dataset included different cell types (endothelial cells, macrophages and epithelial cells) which were isolated from non-paired primary normal colon tissues and colorectal carcinomas and subsequently, RNA was isolated. In this study, we included only endothelial cells and excluded the other cell types from our study. Endothelial cells were isolated using the facs-sorting method. The dataset included 24 samples of endothelial cells, including 10 normal colon samples and 14 colon tumor samples. The platform of this data is GPL4133 (Agilent-014850 whole human genome microarray 4x44K G4112F) with a feature number version. Gene expression profiling interactive analysis (GEPIA) (http://gepia2.cancer-pku.cn/#index) dataset (n = 316) was used for the study of prognostic and expression levels of hub genes [12]. In addition, the correlation between the expression of hub genes and tumor-infiltrating immune cells was explored via gene modules in the TIMER dataset (n = 457) (https://cistrome.shinyapps.io/timer/) [13]. For identifying the gene-gene correlation, we used the TCGA-COAD dataset (n = 287) (https://gdc-portal.nci.nih.gov/) which was normalized into base log2.

    We used the web tool Network Analyst [14]to identify the significant DEGs between CTECs and CNECs. Dataset was normalized by quantile normalization and the R package "limma" was utilized to identify the DEGs between CTECs and CNECs. We utilized the Network Analyst tool to identify the average expression level of single gene having multiple probes in this gene expression study. We identified the DEGs with a threshold of |LogFC| > 0.585 and adjusted P value < 0.05.

    We performed gene-set enrichment analysis of the DEGs by GSEA [15]. We identified the KEGG [16] pathways that were significantly associated with the up-regulated and the down-regulated DEGs, respectively. We identified the significant pathways with a threshold of false discovery rate (FDR) < 0.05.

    To better know the relationship among these screened DEGs, the PPI network was established using the STRING database [17]. The hub genes in the PPI network were identified according to a degree using the node explorer module of Network Analyst software [14]. A hub gene was defined as a gene that was connected to no less than 10 other DEGs. A cytoscape plug-in molecular complex detection (MCODE) was employed to detect the modules from the PPI network [18]. We identified the significant modules based on the MCODE score and node number. The threshold of the MCODE was Node Score Cut-off: 0.2, Haircut: true, K-Core: 2 and maximum depth from Seed: 100.

    We compared the overall survival (OS) and the disease-free survival (DFS) of colon cancer patients classified based on gene expression levels (expression levels > median versus expression levels < median). Kaplan-Meier survival curves were used to show the survival differences and the log-rank test was utilized to evaluate the significance of survival differences. The prognostic roles of screened hub genes in COAD were analyzed using expression profiling interactive analysis (GEPIA) databases [12]. Cox P < 0.05 was considered as significant between two groups of patients.

    The expression levels of top hub genes were further validated using the gene expression profiling interactive analysis (GEPIA), a newly developed interactive web server for analyzing the RNA sequencing data [12]. We used TCGA COAD tumor data with matched normal. Hub genes with |log2FC| > 0.585 and P < 0.05 were considered statistically significant between the two groups.

    We utilized the "ESTIMATE" R package to quantify the immune scores (predict the immune cell quantity) and stromal scores (predict the stromal cells quantity) for each of the tumor samples [19]. Then we calculated Spearman's correlations between the expression levels of prognostic hub genes and immune and stromal scores. The threshold value of correlation is R > 0.30 and P-value is less than 0.001 (Spearman's correlation test).

    We analyzed the significant correlations of hub genes with the abundance of immune infiltrates, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages and dendritic cells, via gene modules in TIMER [13]. In addition, Spearman's correlations between the expression level of hub genes and the immune inhibitory marker genes of tumor-infiltrating immune cells were explored via correlation modules in TIMER [13]. Moreover, we identified pearson's correlations between the expression level of hub genes and the marker genes of inhibitory immune cells in TCGA-COAD datasets using R software. The R package "ggplot2" was employed for drawing a correlation graph [20]. The gene markers of tumor-infiltrating immune cells included markers of monocytes, TAMs, M2 macrophages, T-helper 1 (Th1) cells, Tregs and exhausted T cells. These gene markers are illustrated in prior studies [12,21,22,23,24].

    We used R programming software for the statistical analysis of this study. For the differential expression analysis of gene expression data, only genes with |logFC| > 0.585 and adjusted P-value < 0.05 were considered statistically significant between the two groups. In the survival analysis, Cox P < 0.05 was considered as statistically significant. Spearman's correlation test between the ssGSEA scores and the expression level of specific prognostic genes was performed because these data were not normally distributed (P < 0.05) [25]. For analyzing the correlations between the expression levels of hub genes with the expression levels of other marker genes, we employed Pearson's correlation test because these data were normally distributed [25].

    Based on the log2FC and adjusted P-value, we identified 362 differentially expressed genes (DEGs) in CTECs relative to the CNECs, which included 117 up-regulated genes (Supplementary Table S1) and 245 down-regulated (Supplementary Table S2) in the CTECs samples. Table 1 demonstrates the top ten up-regulated genes (SPARC, IGFBP7, COL4A2, SELE, CXCL1, VWF, CCDC3, FSTL1, VWA1 and IFITM3) with significant statistical description. The most up-regulated gene SPARC is up-expressed in the stromal portion of CRC tissues [26]. The extracellular matrix-associated gene, COL4A2, is linked with cancer stemness [27]. Another up-regulated gene, CXCL1, is associated with increasing the metastatic ability of colon cancer by enhancing cell migration, matrix metalloproteinase-7 expression and EMT [28]. VWF, another up-regulated gene, is a plasma marker for the early detection of adenoma and colon cancer [29]. Table 2 illustrated the top ten down-regulated genes (IGKV1-5, IGLV1-44, IGKC, IGHV3-30, KRT81, IGHG1, IGHM, POU2AF1, IGKV2-24 and IGLJ3) with all significant statistical descriptions. Interestingly, most of the top down-regulated genes are associated with immunological activities. Some other down-regulated genes of CTECs have been demonstrated to be under-expressed in CRC. For example, the expression of POU2AF1 is down-regulated in the rat colon and in turn, reveals proximal-distal differences in the process of histone modifications and proto-oncogene expression [30]. Altogether, abnormally expressed numerous genes in CTECs compared to NTECs identified by the bioinformatic analysis have been associated with CRC pathology and carcinogenesis.

    Table 1.  List of top ten up-regulated genes.
    Entrez ID Symbols logFC P-Value Adjusted P-Value Name of gene
    6678 SPARC 2.21 0.0009 0.029 Secreted protein, acidic, cysteine-rich (osteonectin)
    3490 IGFBP7 2.19 0.0008 0.026 Insulin-like growth factor-binding protein 7
    1284 COL4A2 2.19 0.0002 0.016 Collagen, type IV, alpha 2
    6401 SELE 1.97 0.0017 0.038 Selectin E
    2919 CXCL1 1.85 0.0003 0.018 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
    7450 VWF 1.85 0.0023 0.044 Von Willebrand factor
    83643 CCDC3 1.82 0.0004 0.019 Coiled-coil domain containing 3
    11167 FSTL1 1.68 0.0005 0.022 Follistatin-like 1
    64856 VWA1 1.62 0.0002 0.016 Von Willebrand factor A domain containing 1
    10410 IFITM3 1.59 0.0003 0.018 Interferon-induced transmembrane protein 3

     | Show Table
    DownLoad: CSV
    Table 2.  List of top ten down-regulated genes.
    Entrez ID Symbols logFC P-Value Adjusted P-Value Name of gene
    28299 IGKV1-5 −3.30 0.00058 0.024 Immunoglobulin kappa variable 1−5
    28823 IGLV1-44 −3.28 0.00004 0.009 Immunoglobulin lambda variable 1−44
    3514 IGKC −3.23 0.00020 0.016 Immunoglobulin kappa constant
    28439 IGHV3-30 −3.19 0.00002 0.008 Immunoglobulin heavy variable 330
    3887 KRT81 −3.19 0.00006 0.009 Keratin 81
    3500 IGHG1 −3.07 0.00004 0.009 Immunoglobulin heavy constant gamma 1 (G1m marker)
    3507 IGHM −2.98 0.00017 0.016 Immunoglobulin heavy constant mu
    5450 POU2AF1 −2.91 0.00007 0.010 POU class 2 associating factor 1
    28923 IGKV2-24 −2.75 0.00094 0.029 Immunoglobulin kappa variable 2−24
    28831 IGLJ3 −2.74 0.00032 0.018 Immunoglobulin lambda joining 3

     | Show Table
    DownLoad: CSV

    The functional enrichment analysis identifying the enriched up-regulated and down-regulated biological pathways that are associated with significant DEGs (Figure 1). GSEA pathway analysis revealed nine up-regulated pathways (focal adhesion, ECM-receptor interaction, pathways in cancer, small cell lung cancer, adherens junction, arrhythmogenic right ventricular cardiomyopathy (ARVC), pathogenic escherichia coli infection, cytokine-cytokine receptor interaction and proximal tubule bicarbonate reclamation) (Figure 1A) in CTECs. In addition, we also identified ten down-regulated pathways (protein export, cell adhesion molecules (CAMs), arrhythmogenic right ventricular cardiomyopathy (ARVC), N-Glycan biosynthesis, the intestinal immune network for IgA production, primary immunodeficiency, hypertrophic cardiomyopathy (HCM), ECM-receptor interaction, dilated cardiomyopathy and vasopressin-regulated water reabsorption) in CTECs (Figure 1B). Recently, it was stated that focal adhesion, ECM-receptor interaction, pathways in cancer, small cell lung cancer, adherens junction and cytokine-cytokine receptor interaction pathways are dysregulated in colon tumors stroma [7].

    Figure 1.  KEGG pathway enrichment analysis of significant DEGs. A. Significantly up-regulated pathways in colon tumor endothelial cells. B. Significantly down-regulated pathways in colon tumor endothelial cells. FDR: false discovery rate.

    Using all 362 DEGs, PPI networks were constructed using STRING software and hub genes were identified using the node explorer of network analyst software. Many significant DEGs are involved in the networks (Supplementary Table S3). The identification of hub genes explored that FN1, GAPDH, COL1A1, COL1A2, CTNNB1, LAMB1, LAMC1, SPARC, IGFBP3 and COL4A1 are top up-regulated hub genes and HSP90B1, PDIA6, ITGA4, DDOST, SDC1, CKAP4, CD38, MANF, ITGB7 and CCR2 are top down-regulated hub genes in CTECs respectively (Figure 2 and Table 3). Interestingly, we found that top-up-regulated (Table 1) SPARC also acts as a hub gene in the PPI network. FN1 suppressed apoptosis and promoted viability, invasion and migration of tumor cells in CRC [31]. It was showed that COL1A1 and COL1A2 are associated with colon cancer [32,33]. The high expression levels of CTNNB1 positively correlated with metastasis of colon cancer [34]. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis [35]. Altogether, it may be stated that CTECs-derived these hub genes may contribute to colon cancer pathogenesis.

    Figure 2.  The functional enrichment analysis of MCODE derived clusters. A. PPI interaction of Cluster 1. B. Enrichment of the KEGG pathways in Cluster 1. C. PPI interaction of Cluster 3. D. Enrichment of the 11 KEGG pathways in Cluster 3. E. Interaction of 23 nodes in Cluster 4. F. The enrichment of 11 KEGG pathways in Cluster 4.
    Table 3.  The top ten up-regulated and top ten down-regulated hub genes are associated with PPI.
    Regulatory status Symbols Degree logFC Adjusted P-Value Name of gene
    Up-regulated FN1 65 1.14 0.020 Fibronectin 1
    GAPDH 58 0.73 0.010 Glyceraldehyde-3-phosphate dehydrogenase
    COL1A1 39 1.06 0.041 Collagen, type I, alpha 1
    COL1A2 32 1.01 0.032 Collagen, type I, alpha 2
    CTNNB1 32 0.79 0.007 Catenin (cadherin-associated protein), beta 1, 88kda
    LAMB1 31 1.10 0.021 Laminin, beta 1
    LAMC1 29 0.76 0.031 Laminin, gamma 1 (formerly LAMB2)
    SPARC 27 2.20 0.028 Secreted protein, acidic, cysteine-rich (osteonectin)
    IGFBP3 24 1.47 0.008 Insulin-like growth factor-binding protein 3
    COL4A1 24 1.10 0.017 Collagen, type IV, alpha 1
    Down-regulated HSP90B1 42 −0.83 0.008 Heat shock protein 90kda beta (Grp94), member 1
    PDIA6 32 −0.730 0.041 Protein disulfide isomerase family A, member 6
    ITGA4 25 −0.72 0.020 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
    DDOST 22 −0.78 0.015 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase
    SDC1 21 −1.09 0.009 Syndecan 1
    CKAP4 20 −0.74 0.020 Cytoskeleton-associated protein 4
    CD38 20 −1.48 0.012 CD38 molecule
    MANF 18 −0.67 0.018 Mesencephalic astrocyte-derived neurotrophic factor
    ITGB7 18 −1.89 0.017 Integrin, beta 7
    CCR2 17 −0.73112 0.022 Chemokine (C-C motif) receptor 2

     | Show Table
    DownLoad: CSV

    Moreover, MCODE identified 15 clusters from the original PPI networks. The description of MCODE derived clusters is illustrated in Table 4. The top significant cluster 1 contained 15 nodes and 105 edges (Figure 2 and Table 4). We identified the functional enrichment of KEGG pathways for all clusters by using the GSEA. Interestingly, we found that eight of the clusters out of 15 are associated with the enrichment of KEGG pathways. Gene set of Cluster 1 is related to the enrichment of 4 pathways: ECM-receptor interaction, small cell lung cancer, pathways in cancer and focal adhesion (Figure 2A, B). Cluster 3 (Figure 2C, D), Cluster 4 (Figure 2E, F) and Cluster 9 (Cell adhesion molecules and natural killer cell-mediated cytotoxicity) are associated with the enrichment of immune, stromal and cancer-associated pathways. Some of the enriched pathways in Cluster 3 included ECM-receptor interaction, focal adhesion, small cell lung cancer, cell adhesion molecules, the intestinal immune network for IgA production, pathways in cancer and hematopoietic cell lineage. In addition, some of the pathways enriched in Cluster 4 are the chemokine signaling pathway, adherens junction, cytokine-cytokine receptor interaction, focal adhesion, NOD-like receptor signaling pathway, pathways in cancer, leukocyte trans-endothelial migration and tight junction. Protein export is enriched in Cluster 2 and the B cell receptor signaling pathway is enriched in Cluster 5. Cluster 13 (Fatty acid metabolism and PPAR signaling pathway) and cluster 15 (Glycosphingolipid biosynthesis-Lacto and neolacto series and N-Glycan biosynthesis) are mainly associated with the enrichment of metabolic pathways. Uddin et al. also identified some of these pathways, including pathways in cancer, small cell lung cancer, ECM-receptor interaction, focal adhesion, natural killer cell-mediated cytotoxicity and cell adhesion molecules, are enriched in colon tumor stroma [7,9]. Altogether, it can be stated that this hub PPI from CTECs may contribute to colon carcinogenesis.

    Table 4.  MCODE identified 15 clusters from the PPI networks.
    Cluster Score Nodes Edges Node Ids
    1 15 15 105 FSTL1, IGFBP5, IGFBP3, APLP2, HSP90B1, PDIA6, FN1, PRSS23, TMEM132A, VWA1, CKAP4, LAMB1, IGFBP7, LAMC1, CYR61
    2 9.556 10 43 DDOST, SSR3, SEC61B, SSR4, SPCS2, SPCS1, SPCS3, TRAM1, OSTC, SEC11C
    3 9.2 11 46 ITGA8, ITGA5, COL4A2, LAMA4, COL12A1, COL4A1, SPARC, ITGB7, COL1A1, ITGA4, COL1A2
    4 5.364 23 59 CCR10, SERP1, OS9, DNAJB11, ABCG2, SDF2L1, HERPUD1, SEL1L, ACTG1, MET, GNG7, CCR2, CTNNB1, SDC1, XBP1, MMP1, DNAJB9, APLN, PNOC, CXCL1, TIMP2, CXCL2, SNAI1
    5 4.857 8 17 CD27, CD79A, UCHL1, IGLL5, SLAMF1, SLAMF7, CD81, CD38
    6 4.5 5 9 TUBA1B, CCT2, CCT3, DNAJA4, CCT4
    7 4.5 5 9 CLCA4, ZG16, SLC26A3, GUCA2A, GUCA2B
    8 4 5 8 DERL2, DERL3, ERLEC1, CRELD2, UBE2J1
    9 4 4 6 SPN, CD48, GZMB, CD4
    10 3 3 3 MZB1, TNFRSF17, POU2AF1
    11 3 3 3 FCGBP, CLCA1, RETNLB
    12 3 3 3 PLAC8, RNASET2, CECR1
    13 3 3 3 HMGCS2, ACSL1, ACADVL
    14 3 3 3 IFITM3, IFITM2, ISG20
    15 2.667 4 4 B4GALT3, ST3GAL6, MGAT1, MANEA

     | Show Table
    DownLoad: CSV

    We considered the top ten up-regulated and top ten down-regulated genes from the original PPI network for survival analysis. We selected the TCGA-COAD database for screening OS and DFS. We got COL1A1, COL1A2, IGFBP3, SPARC and DDOST hub genes are significantly involved with patient survival time (Figure 3). We found that the higher expression level of up-regulated COL1A1, COL1A2, IGFBP3 and SPARC are worse for patient's DFS and COL1A2 is also associated with poor OS. In addition, the low expression level of down-regulated DDOST is more inferior for patient's OS and DFS. It showed that higher expressions of COL1A1 were related to poor survival in colon cancer patients [33]. COL1A2 gene is also associated with the prognosis of IIA stage colon cancer [32]. Stromal SPARC had a pro-metastatic impact in vitro and was a characteristic of aggressive tumors with a poor prognosis in CRC patients [26]. Collectively, hub genes of CTECs are prognostic markers in COAD and may be contributed to colon carcinogenesis.

    Figure 3.  Survival analysis of individual hub genes. Up-regulated COL1A1, COL1A2, IGFBP3 and SPARC and down-regulated DDOST have been associated with the poor prognosis in COAD.

    Interestingly, we found that all four up-regulated hub genes (COL1A1, COL1A2, IGFBP3 and SPARC) were consistently up-regulated in TCGA COAD samples versus normal samples (P < 0.05) (Figure 4). It indicates that CTECs may have a contribution to the COAD-derived transcriptomes in colon cancer. However, one of the down-regulated hub genes, DDOST, showed no significant expression differences between TCGA-COAD samples versus normal samples (P < 0.05), suggesting that this hub gene is expressed explicitly in CTECs.

    Figure 4.  Validation of the expression levels of prognostic hub genes between colon cancer and normal tissue (P < 0.05, |Log FC| > 0.585).

    Tumor-infiltrating lymphocytes are independent prognostic factors for better survival and sentinel lymph node status in cancers [36]. Genes highly expressed in the microenvironment are expected to negatively associate with tumor purity, while the opposite is expected for genes highly expressed in the tumor cells [13]. So, we assessed whether the expression of hub genes was correlated with immune infiltration levels in COAD. We investigated the correlations of prognostic hub genes (COL1A1, COL1A2, IGFBP3, SPARC and DDOST) with immune scores and stromal scores in COAD. Interestingly, we found that the expression levels of COL1A1, COL1A2, IGFBP3 and SPARC positively correlated with the immune scores (Figure 5A) and stromal scores (Figure 5B) (Spearman's correlation test, R > 0.30, P < 2.2e−16). This result indicated that the prognostic hub genes are associated with the regulation of the tumor microenvironment.

    Figure 5.  Up-regulated prognostic hub genes are associated with the regulation of the tumor microenvironment in COAD. The expression level of COL1A1, COL1A2, IGFBP3 and SPARC positively correlated with the immune scores (A) and stromal scores (B).

    In addition, we identified the correlations between the expression of hub genes and the immune infiltration levels in COAD by using the TIMER tool. The results discovered that up-regulated COL1A1, COL1A2, IGFBP3 and SPARC expression have significant (P ≤ 0.05) correlations with tumor purity in COAD but down-regulated DDOST not correlated with tumor purity (Figure 6). In addition, COL1A1 expression has significant correlations with infiltrating levels of CD4+ T cells, macrophage, neutrophil and dendritic cells. We also found that a significant positive correlation between COL1A2, IGFBP3 and SPARC expression and infiltration of all five immune cells (CD4+ T cells, CD8+ T cells, Neutrophils, Macrophages and Dendritic cells) in COAD. Besides, we found significant negative correlations between DDOST expression and infiltration of all five immune cells (CD4+ T cells, CD8+ T cells, Neutrophils, Macrophages and Dendritic cells) (Figure 6). Recently it was stated that macrophages and neutrophils are associated with immunosuppressive inflammation to modulate anti-tumor immunity [37]. DCs can promote tumor metastasis by increasing Treg cells and reducing CD8+ T cell cytotoxicity [38]. These results suggest that the expression of COL1A1, COL1A2, IGFBP3, SPARC and DDOST has potential roles in tumor purity and immune cell infiltrations in colon cancer.

    Figure 6.  Hub genes are correlated with immune infiltration level and tumor purity. Expression of COL1A1, COL1A2, SPARC, IGFBP3 and DDOST are significantly negatively correlated to tumor purity and have significant positive correlations with infiltrating levels of CD4+ T cells, macrophages, neutrophils and dendritic cells in COAD. The correlation analyses were performed using TIMER [13]. RSEM: RNA-Seq by Expectation Maximization [39].

    To elucidate the relationship between up-regulated hub genes COL1A1, COL1A2, IGFBP3 and SPARC and the diverse immune infiltrating cells, we find out the correlations between these genes and immune marker sets of various immune cells including monocytes, TAMs, M2 macrophages, Th1, Tregs and T cell exhaustion (Table 5). Surprisingly, we got that the hub genes COL1A1, COL1A2, IGFBP3 and SPARC are positively correlated (Pearson correlation test, P ≤ 0.001) with the immune markers of monocytes, TAMs, M2 macrophages, Th1, Tregs and T cell exhaustion. These findings suggest that the high expression level of hub genes plays an essential role in the infiltration of monocytes, TAMs, M2 macrophages, Th1, Tregs and T cell exhaustion in COAD. It was recently reported that LAYN acts as a prognostic biomarker for determining prognosis and immune infiltration in gastric and colon cancers [21]. Potent immunosuppressive T-regulatory cells (Tregs) are found in a vast array of tumor types and tumor-infiltrating Tregs are often associated with poor clinical outcomes. Tregs also promote cancer progression through their ability to limit anti-tumor immunity and promote angiogenesis [40]. Another marker, FOXP3, plays an important role in Treg cells which leads to the suppression of cytotoxic T cells attacking tumor cells [40]. TIM-3 is a crucial surface protein on exhausted T cells, a critical gene that regulating T cell exhaustion [41].

    Table 5.  Correlation analysis between survival-associated hub genes and markers of immune-inhibitory cells in TCGA-COAD data.
    Immune cell Gene markers SPARC COL1A1 COL1A2 IGFBP3
    R P R P R P R P
    Monocyte CD86 0.69 1.49E−42 0.65 2.71E−35 0.67 3.02E−39 0.55 2.39E−24
    CSF1R 0.71 1.22E−44 0.68 5.80E−41 0.72 1.60E−46 0.59 9.29E−28
    TAM CCL2 0.76 3.55E−56 0.69 1.00E−41 0.72 2.51E−47 0.58 2.49E−27
    CD68 0.49 8.62E−19 0.48 5.34E−18 0.49 1.16E−18 0.46 1.25E−16
    IL10 0.57 1.86E−26 0.52 4.70E−21 0.54 2.65E−23 0.42 1.87E−13
    M2 macrophage CD163 0.71 4.72E−46 0.71 4.11E−46 0.73 7.07E−49 0.52 1.88E−21
    VSIG4 0.73 8.85E−50 0.70 2.16E−43 0.71 6.58E−46 0.56 7.05E−25
    MS4A4A 0.70 2.77E−44 0.65 1.77E−35 0.67 7.62E−39 0.54 6.22E−23
    Th1 T-bet (TBX21) 0.36 3.16E−10 0.38 1.66E−11 0.38 3.46E−11 0.37 8.76E−11
    IFN-γ (IFNG) 0.18 0.001 0.21 0.00040 0.20 0.000834 0.16 0.00589
    TNF-α (TNF) 0.40 3.37E−12 0.38 1.65E−11 0.40 3.16E−12 0.21 0.00030
    Treg FOXP3 0.56 6.11E−25 0.55 3.52E−24 0.58 1.49E−27 0.50 1.01E−19
    CCR8 0.56 1.13E−24 0.54 4.14E−23 0.58 2.02E−27 0.48 1.23E−17
    TGFβ (TGFB1) 0.74 1.08E−50 0.73 1.99E−49 0.75 1.61E−52 0.62 6.64E−32
    T cell exhaustion PD-1 (PDCD1) 0.32 3.27E−08 0.32 2.35E−08 0.33 9.61E−09 0.35 8.10E−10
    CTLA4 0.42 1.40E−13 0.42 1.10E−13 0.44 7.38E−15 0.40 3.58E−12
    LAG3 0.25 1.56E−05 0.29 6.10E−07 0.28 1.94E−06 0.27 3.07E−06
    TIM-3(HAVCR2) 0.70 1.48E−43 0.67 2.34E−38 0.69 3.05E−41 0.54 1.58E−23
    TIGIT 0.39 4.84E−12 0.41 7.99E−13 0.42 5.46E−14 0.40 2.49E−12
    CXCL13 0.35 1.82E−09 0.36 5.46E−10 0.35 8.72E−10 0.31 1.34E−07
    LAYN 0.89 2.42E−97 0.79 1.39E−63 0.83 4.05E−75 0.67 2.35E−38
    *Note: R is Pearson correlation and P is p-value in Pearson's correlation test.

     | Show Table
    DownLoad: CSV

    Since the elevated expression of prognostic hub genes were positively associated with the immune inhibitory markers PD-1 and TGFB1 (Table 5), we expect the expression levels of PD-L1 (CD274), PD-L2 (PDCD1LG2) and TGFBR1 could be positively associated with the prognosis-associated hub genes. Interestingly, we found that PDL1 (CD274), PDL2 (PDCD1LG2) and TGFBR1 are moderate to highly correlated with all four-prognosis related highly expressed hub genes: COL1A1, COL1A2, SPARC and IGFBP3 (Figure 7). T cell immunity recovered by PD-1/PD-L1 immune checkpoint blockade has been demonstrated to be a promising cancer therapeutic strategy [42]. The expression of PD-L2 was observed in tumors, stroma and endothelial cells and PD-L2 expression is relevant to anti-PD-1 therapy in cancer [43]. TGFBR1 is one of the receptors for TGF-β ligands. The TGF-β signaling pathway is crucially associated with stimulation, induction and maintenance of EMT in cancers [44]. TGFBR1 is up-regulated in multiple malignancies and dysregulation of TGFBR1 leads to tumorigenesis by controlling cellular signaling, which in turn is associated with colorectal cancer risk [45]. Altogether, it suggests that the prognostic associated hub genes may regulate the immune-suppressive activities of TME through the interactions with the immune marker in colon cancer.

    Figure 7.  Prognostic hub genes are significantly positively correlated with immune suppressive PD-L1, PD-L2 and TGFBR1. Up-regulated four hub genes (SPARC, COL1A2, COL1A2 and IGFBP3) are significantly correlated with three prominent immune-inhibitory markers (PD-L1, PD-L2 and TGFBR1). The correlation analyses were performed using R software. The Pearson's correlation test p-values (P) and correlation coefficients (R) are shown in the figure.

    TECs are the substantial component of tumor stroma in TME and these cells are associated with tumor malignancies, progression and metastasis [5]. This present study conducted a differential expression analysis using gene expression profiling data from the GEO database. We identified 362 DEGs in CTECs, including 117 up-regulated genes (SPARC, COL4A2, CXCL1 and VWF) and 245 down-regulated genes. Interestingly, we found that many immunological genes are down-regulated in CTECs (Table 2). Subsequent pathway enrichment analysis revealed that up-regulated DEGs were significantly enriched with cancer, cellular development and immune regulation. Down-regulated DEGs were enriched considerably with mostly immunodeficiency and metabolism-related pathways (Figure 1). These results revealed the abnormal cellular growth, immune regulatory, cancerous and metabolism-associated pathways in CTECs.

    Next, we employed DEGs to construct a PPI network and extracted significant clusters from the original PPI network (Figure 2). Finally, we identified hub genes (degree > 10) that are dysregulated in CTECs. We identified CTECs-derived five hub genes (COL1A1, COL1A2, SPARC, IGFBP3 and DDOST) whose expression was significantly associated with the poor prognosis in TCGA-COAD data (Figure 3). These hub genes are mainly involved in protein digestion and absorption (COL1A1 and COL1A2), cellular signaling (SPARC and IGFBP3) and enzymatic action of metabolism (DDOST), suggesting that the deregulation of these cellular functions in CTECs may contribute to the altered prognosis in colon cancer. In addition, the expression analysis of these prognostic hub genes in colon cancer was further evaluated using the GEPIA database [12]. We found that four hub genes (COL1A1, COL1A2, SPARC and IGFBP3) are also significantly up-regulated in TCGA-COAD samples. Still, another down-regulated hub gene (DDOST) is not considerably down-regulated in TCGA-COAD samples (Figure 4). It indicates that CTECs-associated gene signature substantially contributed to colon carcinogenesis.

    Furthermore, our study showed that the immune infiltration levels and diverse immune marker sets are correlated with the expression levels of COL1A1, COL1A2, SPARC and IGFBP3 hub genes. Our analysis demonstrated that a significant positive correlation between the COL1A1, COL1A2, SPARC and IGFBP3 expression levels and infiltration level of CD4+ T cells, macrophages, neutrophils and DCs in COAD (Figure 6). These results are suggesting that the potential immunological roles of hub genes in colon TME. In addition, our study indicated that COL1A1, COL1A2, SPARC and IGFBP3 could activate Tregs and induce T cell exhaustion. The increase in up-regulated four hub genes expression positively correlates with Treg and T cell exhaustion markers (Table 5). Other markers of monocytes, TAM, M2 macrophage, Th1, are also positively correlated with the expression of these hub genes (Table 5). Some other crucial immune inhibitory markers, PD-L1, PD-L2 and TGFBR1, are significantly correlated with the expression level of COL1A1, COL1A2, SPARC and IGFBP3 (Figure 7). Altogether, the prognostic hub genes are associated with immunosuppressive colon TME.

    Since our analysis identified numerous CTECs-derived transcriptomes that are critically associated with colon cancer, we speculated that the endothelial cells might contribute to the other vascular pathologies, including the central nervous system (CNS) and other diseases. It was stated that cerebral endothelial cells play an active role in the pathogenesis of CNS inflammatory diseases [46]. Endothelial cells are associated with the leukocyte migration in CNS and regulating the leukocyte-endothelial cell interactions and the crosstalk between endothelial cells and glial cells or platelets in CNS [46]. The major vascular anomalies of the nervous system included cerebral cavernous malformations (CCMs) and arteriovenous malformations (AVMs) [47,48]. These CNS-associated vascular diseases are characterized by genetic alterations, such as gene polymorphisms and mutations [47,48,49,50,51]. For example, germline mutation enrichment in pathways controlling the endothelial cell homeostasis in patients with brain arteriovenous malformation [48]. Altogether, our findings may provide insights to find the roles of endothelial cells in diseases, including cancer, CNS-associated disease and other vascular pathologies.

    This study identified numerous deregulated transcriptomes in the CTECs that could be used as biomarkers for the diagnosis and prognosis of colon cancer and may provide therapeutic targets for colon cancer. However, to translate these findings into clinical application, further experimental and clinical validation would be necessary.

    In summary, we identified potential CTECs-derived significantly deregulated transcriptomes that are involving with the pathogenesis, prognosis and immune inhibition within the tumor microenvironment of colon cancer. This study reveals a potential regulatory mechanism of CTECs in the tumor microenvironment of colon cancer and may contribute to revealing CTECs-colon cancer cellular cross-talk.

    The authors declare no conflict of interest.

    We thank all laboratory staff and technicians for their participation in this study. The present study was supported by the project from Xinjiang Health Poverty Alleviation Work Appropriate Technology Promotion (Grant no. SYTG-Y202035).

    Jie Wang and Md. Nazim Uddin contributed equally to this work. Jie Wang and Md. Nazim Uddin conceived the research, designed analysis strategies. Rehana Akter wrote the manuscript and Yun Wu conceived the study and wrote the manuscript. All the authors read and approved the final manuscript.

    [1] Bonafini S, Fava C (2015) Home blood pressure measurements: Advantages and disadvantages compared to office and ambulatory monitoring. Blood Press 24: 325–332. doi: 10.3109/08037051.2015.1070599
    [2] Wolak T, Wilk L, Paran E, et al. (2013) Is it possible to shorten ambulatory blood pressure monitoring? J Clin Hypertens (Greenwich) 15: 570–574. doi: 10.1111/jch.12123
    [3] O'Brien E, Parati G, Stergiou G, et al. (2013) European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31: 1731–1768. doi: 10.1097/HJH.0b013e328363e964
    [4] Norma M Kaplan, George Tomas, Marc Pohl, et al. (2016) Blood pressure measurement in the diagnosis and management of hypertension in adults.
    [5] Krause T, Lovibond K, Caulfield M, et al. (2011) Management of hypertension: summary of NICE guidance. BMJ (Clinical Res) 343: 1–6.
    [6] Siu AL, U.S. Preventive Services Task Force (2015) Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 163: 778–786.
    [7] Chobanian AV, Bakris GL, Black HR, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2
    [8] Kaplan NM, Townsend RR (2015) Ambulatory and home blood pressure monitoring and white coat hypertension in adults.
    [9] Hermida RC, Ayala DE, Portaluppi F (2007) Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. Advance Drug Delivery Rev 9: 904–922.
    [10] Andersen MJ, Khawandi W, Agarwal R (2005) Home blood pressure monitoring in CKD. Am J Kidney Dis 45: 994–1001. doi: 10.1053/j.ajkd.2005.02.015
    [11] Pickering TG, Miller NH, Ogedegbe G, et al. (2008) Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52: 10–29. doi: 10.1161/HYPERTENSIONAHA.107.189010
    [12] Parati G, Pickering TG (2009) Home blood-pressure monitoring: US and European consensus. Lancet 373: 876–878. doi: 10.1016/S0140-6736(09)60526-2
    [13] Niiranen TJ, Hänninen MR, Johansson J, et al. (2010) Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The finn-home study. Hypertension 55: 1346–1351. doi: 10.1161/HYPERTENSIONAHA.109.149336
    [14] Verberk WJ, Kroon AA, Kessels AGH, et al. (2005) Home blood pressure measurement: A systematic review. J Am College Cardiology 46: 743–751. doi: 10.1016/j.jacc.2005.05.058
    [15] Myers MG (2010) A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertension 28: 703–708. doi: 10.1097/HJH.0b013e328335d091
    [16] Powers BJ, Olsen MK, Smith VA, et al. (2011) Measuring blood pressure for decision making and quality reporting: Where and how many measures? Ann Intern Med 154: 781–788. doi: 10.7326/0003-4819-154-12-201106210-00005
    [17] Mesas A E, Leon-muñoz L, Rodriguez-artalejo F, et al. (2011) The effect of coffee on blood pressure and cardiovascular disease among hypertensive individuals: Meta-analysis. J Clinical Hypertension 13: A42. doi: 10.1111/j.1751-7176.2010.00379.x
    [18] Other U (2001) Blood pressure measurement. BMJ 322: 1043–1047. doi: 10.1136/bmj.322.7293.1043
    [19] Pickering TG, Hall JE, Appel LJ, et al.(2005) Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on high blood pressure research professional and public education subcommittee.J Cinical Hypertens 7: 102–109.
    [20] Mancia G, Fagard R, Narkiewicz K, et al. (2013) ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc
    [21] Mancia G, De Backer G, Dominiczak A, et al. (2007) ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25: 1751–1762. doi: 10.1097/HJH.0b013e3282f0580f
    [22] O'Brien (2005) Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23: 697–701. doi: 10.1097/01.hjh.0000163132.84890.c4
    [23] U.S. Preventive Services Task Force (2007) Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 147(11):783–786.
    [24] Franklin SS, Thijs L, Hansen TW, et al. (2013) White-coat hypertension new insights from recent studies. Hypertension 62: 982–987. doi: 10.1161/HYPERTENSIONAHA.113.01275
    [25] NICE (2011) Hypertension in adults: diagnosis and management. NICE Guidel :1–38.
    [26] James PA, Oparil S, Carter BL, et al. (2013) Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Jama 1097: 1–14.
    [27] Coca A, Bertomeu V, Dalfó A, et al. (2007)Blood pressure self measurement: Spanish consensus document. Nefrol Publicación La Soc Española Nefrol 27: 139–153
    [28] Bangalore S, Qin J, Sloan S, et al. (2010) What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 122: 2142–2151. doi: 10.1161/CIRCULATIONAHA.109.905687
    [29] Vokó Z, Bots ML, Hofman A, et al. (1999) shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 34: 1181–1185. doi: 10.1161/01.HYP.34.6.1181
    [30] Pahor M, Shorr RI, Cushman WC, et al. (1999) The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 159: 2004–2009. doi: 10.1001/archinte.159.17.2004
    [31] Pickering TG (1988) The influence of daily activity on ambulatory blood pressure. Am Hear Jan 116: 1141–1146. doi: 10.1016/0002-8703(88)90178-0
    [32] Agarwal R, Andersen M (2006) Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 69: 1175–1180. doi: 10.1038/sj.ki.5000247
    [33] Asayama K, Ohkubo T, Kikuya M, et al (2004) Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: The Ohasama study. Stroke 35: 2356–2361. doi: 10.1161/01.STR.0000141679.42349.9f
    [34] Agarwal R, Bills JE, Hecht TJW, et al. (2011) Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control. Hypertension 57: 29–38. doi: 10.1161/HYPERTENSIONAHA.110.160911
    [35] Uhlig K, Patel K, Ip S, et al. (2013) Self-Measured Blood Pressure Monitoring in the Management of Hypertension. A systematic review and meta-analysis. Improve Patient Care 159.
    [36] Cappuccio FP, Kerry SM, Forbes L, et al. (2004) Blood pressure control by home monitoring: meta-analysis of randomised trials. Br Med J 329: 145. doi: 10.1136/bmj.38121.684410.AE
    [37] Powers BJ, Adams MB, Svetkey LP, et al. (2009) Two Self-management Interventions to Improve Hypertension Control. Ann Intern Med 151: 687–696. doi: 10.7326/0000605-200911170-00148
    [38] McManus RJ, Mant J, Haque MS, et al.(2014) Effect of Self-monitoring and Medication Self-titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular Disease. Jama 312: 799.
    [39] McManus RJ, Mant J, Bray EP, et al (2010) Telemonitoring and self-management in the control of hypertension (TASMINH2): A randomised controlled trial. Lancet 376: 163–172. doi: 10.1016/S0140-6736(10)60964-6
    [40] Yi SS, Tabaei BP, Angell SY, et al. (2015) Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record. Circulation 138–145.
    [41] Parati G, Stergiou GS, Asmar R, et al. (2010) European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 24: 779–785. doi: 10.1038/jhh.2010.54
    [42] Dasgupta K, Quinn RR, Zarnke KB, et al.(2014) The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30: 485–501.
    [43] Daskalopoulou SS, Rabi DM, Zarnke KB, et al. (2015) The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol 31: 549–568. doi: 10.1016/j.cjca.2015.02.016
    [44] Avenue G (2011) Optimal Schedule for Home Blood Pressure Measurement. Hypertension 1081–1086.
    [45] Lauer RM, Clarke WR (1989) Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 84: 633–641.
    [46] Sun SS, Grave GD, Siervogel RM, et al. (2007) Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 119: 237–246. doi: 10.1542/peds.2006-2543
    [47] Blumenthal S, Epps R, Heavenrich R (1987) Report of the Second Task Force on Blood Pressure Control in Children. Pediatrics 79: 797–820.
    [48] The Fourth Report on the Diagnosis, Evaluation and T of HBP in C and A (2004) National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics 114: 555–576. doi: 10.1542/peds.114.2.S2.555
    [49] Rosner B, Prineas RJ, Loggie JMH, et al. (1993) Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 123(6): 871–886.
    [50] Joseph T Flynn (2017) Ambulatory blood pressure monitoring in children.
    [51] Williams CL, Daniels SR, Robinson TN, et al. (2002) Cardiovascular health in childhood. A statement for health professionals from the committee on atherosclerosis, hypertension, and obesity in the young of the council on cardiovascular disease in the young, Americam Heart Association. Circulation 106: 143–160.
    [52] Flynn JT (2011) Ambulatory blood pressure monitoring in children: imperfect yet essential. Pediatr Nephrol 26: 2089–2094. doi: 10.1007/s00467-011-1984-9
    [53] Sorof JM, Poffenbarger T, Franco K, et al. (2001) Evaluation of white coat hypertension in children: Importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens 14: 855–860. doi: 10.1016/S0895-7061(01)02180-X
    [54] Lande MB, Meagher CC, Fisher SG, et al. (2008) Left ventricular mass index in children with white coat hypertension. J Pediatr153: 50–54.
    [55] Seeman T, Palyzová D, Dušek J, et al. (2017) Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. J Pediatr 147: 366–371.
    [56] Flynn J, Daniels S, Hayman L, et al.(2014) Update: Ambulatory blood pressure monitoring in children and adolescents: A scientific statement from the American Heart Association. Hypertension 63: 1116–1135.
    [57] Urbina E, Alpert B, Flynn J, et al. (2008) Ambulatory Blood Pressure Monitoring in Children and Adolescents: Recommendations for Standard Assessment: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovas. Hypertension 52: 433–451. doi: 10.1161/HYPERTENSIONAHA.108.190329
    [58] Aronow WS, Fleg JL, Pepine CJ, et al. (2011) Expert Consensus Document ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Am College Cardiology 57: 2037–2114. doi: 10.1016/j.jacc.2011.01.008
    [59] Ishikawa J, Ishikawa Y, Edmondson D, et al. (2011) Age and the difference between awake ambulatory blood pressure and office blood pressure: a meta-analysis. Blood Press Monit 16: 159–167. doi: 10.1097/MBP.0b013e328346d603
    [60] Stergiou GS, Ntineri A, Kollias A (2017) Changing relationship among office, ambulatory, and home blood pressure with increasing age: A neglected issue. Hypertension 64: 931–932.
    [61] US Preventive Services Task Force (2017) Final Recommendation Statement: High Blood Pressure in Adults.
    [62] Weber MA, Schiffrin EL, White WB, et al. (2014) Clinical Practice Guidelines for the Management of Hypertension in the Community. J Clin Hypertens 16: 14–26. doi: 10.1111/jch.12237
    [63] Bangalore S, Messerli FH, Wun CC, et al. (2010) J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31: 2897–2908. doi: 10.1093/eurheartj/ehq328
    [64] Maselli M, Giantin V, Franchin A, et al. (2014) Detection of blood pressure increments in active elderly individuals: the role of ambulatory blood pressure monitoring. Nutr Metab Cardiovasc Dis 24: 914–920. doi: 10.1016/j.numecd.2014.01.003
    [65] Angeli F, Reboldi G, Verdecchia P (2010) Masked hypertension: Evaluation, prognosis, and treatment. Am J Hypertens 23: 941–948. doi: 10.1038/ajh.2010.112
    [66] Cacciolati C, Hanon O, Alpérovitch A, et al. (2011) Masked hypertension in the elderly: cross-sectional analysis of a population-based sample. Am J Hypertens 24: 674–680. doi: 10.1038/ajh.2011.23
    [67] Verberk WWJ, Omboni S, Kollias A, et al. (2016) Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations. Int J Cardiol 203: 465–473. doi: 10.1016/j.ijcard.2015.10.182
    [68] Calhoun D A, Jones D, Textor S, et al. (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 117: 1403–1419.
    [69] De la Sierra A, Segura J, Banegas JR, et al.(2011) Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898–902.
    [70] Jiménez Navarro MF (2016) Comentarios a la guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Española Cardiol 69: 894–899. doi: 10.1016/j.recesp.2016.08.009
    [71] Pickering TG (1988) Blood pressure monitoring outside the office for the evaluation of patients with resistant hypertension. Hypertension 11: II96-100.
    [72] Lazaridis AA, Sarafidis PA, Ruilope LM (2015) Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance? Curr Hypertens Rep 17.
    [73] Brown MA, Buddle ML, Martin A (2001) Is resistant hypertension really resistant? Am J Hypertens 14: 1263–1269. doi: 10.1016/S0895-7061(01)02193-8
    [74] Ríos M, Domínguez-Sardiña M, Ayala D, et al. (2013) Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 30.
    [75] Cardoso CRL, Salles GF (2016) Prognostic Importance of Ambulatory Blood Pressure Monitoring in Resistant Hypertension: Is It All that Matters? Curr Hypertens Rep 18: 85. doi: 10.1007/s11906-016-0693-y
    [76] Salles GF, Cardoso CL, Muxfeldt ES (2008) Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 168: 2340–2346. doi: 10.1001/archinte.168.21.2340
    [77] Ayala DE, Hermida RC, Mojón A, et al. (2012) Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure–Lowering Medications. Chronobiol Int 528: 1–13.
    [78] Calhoun DA, Raymond MD, Townsens MD (2016) Treatment of resistant hypertension.
    [79] Doroszko A, Janus A, Szahidewicz-Krupska E, et al. (2016) Resistant hypertension. Adv Clin Exp Med 25: 173–183. doi: 10.17219/acem/58998
    [80] Muxfeldt E, Bloch K, Nogueira A, et al. (2003) Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 8: 181–185.
    [81] Muxfeldt ES, Salles GF (2013) How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res 36: 385–389. doi: 10.1038/hr.2013.17
    [82] Williams B, Macdonald TM, Morant S, et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (Pathway-2): A randomised, double-blind, crossover trial. Lancet 386: 2059–2068. doi: 10.1016/S0140-6736(15)00257-3
    [83] Dudenbostel T, Siddiqui M, Oparil S, et al. (2016) Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 67: 1085–1092. doi: 10.1161/HYPERTENSIONAHA.116.06587
    [84] Hermida RC, Smolensky MH, Ayala DE, et al. (2013) Recomendaciones 2013 para el uso de la monitorización ambulatoria de la presión arterial para el diagnóstico de hipertensión en adultos, valoración de riesgo cardiovascular y obtención de objetivos terapéuticos (resumen). Clínica e Investig en Arterioscler 25: 74–82. doi: 10.1016/j.arteri.2013.03.002
    [85] Sheikh S, Sinha A, Agarwal R (2011) Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk? Curr Hypertens Rep 13: 192–199. doi: 10.1007/s11906-011-0193-z
    [86] Hermida RC, Moyá A, Ayala DE (2015) Monitorización ambulatoria de la presión arterial en diabetes para valoraci??n y control de riesgo vascular. Endocrinologiay Nutricion 62: 400–410.
    [87] Mancia G, Verdecchia P (2015) Clinical Value of Ambulatory Blood Pressure: Evidence and Limits. Circ Res 116: 1034–1045. doi: 10.1161/CIRCRESAHA.116.303755
    [88] Leitão CB, Canani LH, Silveiro SP, et al. (2007) Ambulatory blood pressure monitoring and type 2 diabetes mellitus. Arq Bras Cardiol 89: 315–321, 347–354
    [89] Care D (2016) Standards of Medical Care in Diabetes : Summary of Revisions. Diabetes Care 39: S4–5. doi: 10.2337/dc16-S003
    [90] Coca A, Camafort M, Doménech M, et al. (2013) Ambulatory blood pressure in stroke and cognitive dysfunction. Curr Hypertens Rep 15: 150–159. doi: 10.1007/s11906-013-0346-3
    [91] Castilla-Guerra L, Fernández-Moreno M del C, Espino-Montoro A, et al. (2009) Ambulatory blood pressure monitoring in stroke survivors: Do we really control our patients? Eur J Intern Med 20: 760–763. doi: 10.1016/j.ejim.2009.09.004
    [92] Castilla-Guerra L, Fernandez-Moreno (2016) Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J stroke 18: 31–37. doi: 10.5853/jos.2015.01102
    [93] Agarwal R (2009) Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens 18: 507–512. doi: 10.1097/MNH.0b013e3283319b9d
    [94] Agarwal R, Peixoto AJ, Santos SFF, et al. (2009) Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit 14: 2–11. doi: 10.1097/MBP.0b013e3283262f58
    [95] Parati G, Ochoa JE, Bilo G, et al.(2016) Hypertension in chronic kidney disease part 1: Out-of-office blood pressure monitoring: Methods, thresholds, and patterns. Hypertension 67: 1093–1101.
    [96] Mehta R, Drawz PE (2011) Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? Curr Hypertens Rep 13: 378–385. doi: 10.1007/s11906-011-0217-8
    [97] Verdecchia P (2000) Prognostic value of ambulatory blood pressure : current evidence and clinical implications. Hypertension 35: 844–851. doi: 10.1161/01.HYP.35.3.844
    [98] O'Brien E, Sheridan J, O'Malley K (1988) Dippers and Non-dippers. Lancet 332: 397.
    [99] Kario K, Pickering TG, Umeda Y, et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 107: 1401–1406. doi: 10.1161/01.CIR.0000056521.67546.AA
    [100] Muller JE, Abela GS, Nesto RW, et al. (1994)Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am College Cardiology 23: 809–813.
    [101] Li Y, Thijs L, Hansen TW, et al. (2010) Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 55: 1040–1048. doi: 10.1161/HYPERTENSIONAHA.109.137273
    [102] Neutel JM, Schnaper H, Cheung DG, et al. (1990) Antihypertensive effects of β-blockers administered once daily: 24-hour measurements. Am Heart J 120: 166–171. doi: 10.1016/0002-8703(90)90174-V
    [103] Meredith PA, Donnelly R, Elliott HL, et al. (1990) Prediction of the antihypertensive response to enalapril. J Hypertens 8: 1085–1090. doi: 10.1097/00004872-199012000-00003
    [104] Hermida RC, Calvo C, Ayala DE, et al. (2005) Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 23: 1913–1922. doi: 10.1097/01.hjh.0000182522.21569.c5
    [105] Kikuya M, Ohkubo T, Asayama K, et al. (2005) Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 45: 240–245. doi: 10.1161/01.HYP.0000152079.04553.2c
    [106] Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. (2007) Predictors of All-Cause Mortality in Clinical Ambulatory Monitoring. Hypertension 49: 1235–1241. doi: 10.1161/HYPERTENSIONAHA.107.087262
    [107] Boggia J, Li Y, Thijs L, et al.(2007) Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370: 1219–1229.
    [108] Fagard RH, Celis H, Thijs L, et al. (2008) Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51: 55–61. doi: 10.1161/HYPERTENSIONAHA.107.100727
    [109] Fan H-Q, Li Y, Thijs L, et al. (2010) Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 28: 2036–2045. doi: 10.1097/HJH.0b013e32833b49fe
    [110] Hermida RC, Ayala DE, Mojón A, et al. (2011) Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 58: 1165–1173. doi: 10.1016/j.jacc.2011.04.043
    [111] Hermida RC, Ayala DE, Mojón A, et al. (2010) Influence of circadian time of hypertension treatment on cardiovascular risk:results of the MAPEC study. Chronob 278: 1629–1651.
    [112] Hermida RC, Ayala DE, Mojón A, et al. (2011) Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34: 1270–1276. doi: 10.2337/dc11-0297
    [113] Hermida RC, Ayala DE, Mojon A, et al. (2011) Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. J Am Soc Nephrol 22: 2313–2321. doi: 10.1681/ASN.2011040361
    [114] Pogue V, Rahman M, Lipkowitz M, et al. (2008) Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease. Hypertension 53.
    [115] Hermida RC (2007)Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int 24: 749–775.
    [116] Minutolo R, Gabbai FB, Borrelli S, et al.(2007) Changing the Timing of Antihypertensive Therapy to Reduce Nocturnal Blood Pressure in CKD: An 8-Week Uncontrolled Trial. Am J Kidney Dis 50: 908–917.
    [117] Hermida RC, Ayala DE, Fernández JR, et al. (2008) Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51: 69–76. doi: 10.1161/HYPERTENSIONAHA.107.096933
    [118] Carter BL, Chrischilles EA, Rosenthal G, et al. (2014) Efficacy and Safety of Nighttime Dosing of Antihypertensives: Review of the Literature and Design of a Pragmatic Clinical Trial. J Clin Hypertens 16: 115–121. doi: 10.1111/jch.12238
    [119] Ohkubo T, Imai Y, Tsuji I, et al. (1997) Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 15: 357–364. doi: 10.1097/00004872-199715040-00006
    [120] Guidelines JCS (2012) Guidelines for the Clinical Use of 24 Hour Ambulatory Blood Pressure Monitoring (ABPM) (JCS 2010). Circ J 76: 508–519. doi: 10.1253/circj.CJ-88-0020
    [121] Verdecchia P, Angeli F, Mazzotta G, et al. (2012) Day-night dip and early-morning surge in blood pressure in hypertension: Prognostic implications. Hypertension :34–42.
    [122] Glynn LG, Murphy AW, Smith SM, et al. (2010) Interventions used to improve control of blood pressure in patients with hypertension. The Cochrane.
    [123] Santschi V, Chiolero A, Colosimo AL, et al. (2014) Improving Blood Pressure Control Through Pharmacist Interventions: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 3: e000718. doi: 10.1161/JAHA.113.000718
    [124] Floras JS (2007) Ambulatory blood pressure: facilitating individualized assessment of cardiovascular risk. J Hypertens 25: 1565–1568. doi: 10.1097/HJH.0b013e32829baafe
    [125] Home. Available from: https://medicalhomeinfo.aap.org/Pages/default.aspx
    [126] Ahern DK, Stinson LJ, Uebelacker LA, et al. (2012) E-health blood pressure control program. J Med Pract Manag 28: 91–100.
    [127] Anthony CA, Polgreen LA, Chounramany J, et al. (2015) Outpatient blood pressure monitoring using bi-directional text messaging. J Am Soc Hypertens 9: 375–381. doi: 10.1016/j.jash.2015.01.008
    [128] Zullig LL, Dee Melnyk S, Goldstein K, et al. (2013) The role of home blood pressure telemonitoring in managing hypertensive populations. Curr Hypertens Rep 15: 346–355. doi: 10.1007/s11906-013-0351-6
    [129] Margolis KLK, Asche SES, Bergdall AAR, et al. (2013) Effect of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Control. Jama 310: 46. doi: 10.1001/jama.2013.6549
    [130] Margolis KLK, Asche SES, Bergdall ARA, et al (2015) A Successful Multifaceted Trial to Improve Hypertension Control in Primary Care: Why Did it Work? J Gen Intern Med 30: 1665–1672. doi: 10.1007/s11606-015-3355-x
    [131] Green B, Cook A, Ralston J, et al. (2008) Effectiveness of Home Blood Pressure Monitoring, Web Communication, and Pharmacist Care on Hypertension Control: The e-BP Randomized Controlled Trial. Jama 299: 2857–2867. doi: 10.1001/jama.299.24.2857
    [132] Fishman PA, Cook AJ, Anderson ML, et al. (2013) Improving BP control through electronic communications: An economic evaluation. Am J Manag Care 19: 709–716.
    [133] Polgreen LA, Han J, Carter BL, et al. (2015) Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control. Hypertension 66: 1145–1151.
    [134] Robins LS, Jackson JE, Green BB, et al. (2013) Barriers and facilitators to evidence-based blood pressure control in community practice. J Am Board Fam Med 26: 539–557. doi: 10.3122/jabfm.2013.05.130060
    [135] Magid D J, Olson K L, Billups S J, et al. (2013) A pharmacist-led, American heart association Heart360 web-enabled home blood pressure monitoring program. Circulation 6: 157–163.
    [136] Bosworth H B, Powers B J, Olsen M K, et al. (2011) Home blood pressure management and improved blood pressure control: Results from a randomized controlled trial. Arch Int Med 171: 1173–1180. doi: 10.1001/archinternmed.2011.276
    [137] Omboni S, Sala E (2015) The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ther13: 209–221.
    [138] Ernst ME (2013) Ambulatory blood pressure monitoring: recent evidence and clinical pharmacy applications. Pharmacotherapy 33: 69–83. doi: 10.1002/phar.1167
    [139] James K, Dolan E, O'Brien E (2014). Making ambulatory blood pressure monitoring accessible in pharmacies. Blood Press Monit 19: 134–139. doi: 10.1097/MBP.0000000000000034
    [140] Gregoski MJ, Vertegel A, Shaporev A, et al. (2013) Tension Tamer: delivering meditation with objective heart rate acquisition for adherence monitoring using a smart phone platform. J Altern Complement Med 19: 17–19. doi: 10.1089/acm.2011.0772
    [141] Rifkin DE, Abdelmalek JA, Miracle CM, et al. (2013) Linking clinic and home: a randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension. Blood Press Monit 18: 8–15. doi: 10.1097/MBP.0b013e32835d126c
    [142] Kim KB, Han HR, Huh B, et al. (2014). The effect of a community-based self-help multimodal behavioral intervention in Korean American seniors with high blood pressure. Am J Hypertens 27: 1199–1208. doi: 10.1093/ajh/hpu041
    [143] Sieverdes JC, Treiber F, Jenkins C, et al. (2013). Improving Diabetes Management With Mobile Health Technology. Am J Med Sci 345: 289–295. doi: 10.1097/MAJ.0b013e3182896cee
    [144] O'Reilly DJ, Bowen JM, Sebaldt RJ, et al. (2014) Evaluation of a Chronic Disease Management System for the Treatment and Management of Diabetes in Primary Health Care Practices in Ontario: An Observational Study. Ont Heal Technol Assess Ser14: 1–37.
    [145] Green BB, Anderson ML, Cook AJ, et al. (2014) E-care for heart wellness: A feasibility trial to decrease blood pressure and cardiovascular risk. Am J Prev Med 46: 368–377. doi: 10.1016/j.amepre.2013.11.009
    [146] Gandhi PU, Pinney S (2014) Management of chronic heart failure: biomarkers, monitors, and disease management programs. Ann Glob Heal 80: 46–54. doi: 10.1016/j.aogh.2013.12.005
    [147] Aberger EW, Migliozzi D, Follick MJ, et al. (2014). Enhancing Patient Engagement and Blood Pressure Management for Renal Transplant Recipients via Home Electronic Monitoring and Web-Enabled Collaborative Care. Telemed J e-Health 20: 850–854. doi: 10.1089/tmj.2013.0317
    [148] Neumann CL, Schulz EG (2014) Interventionelles dezentrales Telemonitoring: Mögliche Indikationen und Perspektiven einer neuen Methode in der Telemedizin. Praxis 103: 519–526. doi: 10.1024/1661-8157/a001642
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7230) PDF downloads(1072) Cited by(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog